Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited
If approved, crinecerfont will be the first new treatment option for CAH in 70 years and represents a novel therapeutic approach, offering a new treatment method for this rare and severe endocrine disorder.